{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:45:53Z","timestamp":1782179153315,"version":"3.54.5"},"reference-count":73,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":75,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comorbidity between epilepsy and infectious diseases in children is frequent. Pharmacokinetic drug\u2010drug interactions (DDIs) between antiseizure medications (ASMs) and anti\u2010infectives can occur and influence their efficacy or cause toxicity. All potential DDIs between ASMs and antimicrobial agents used in children were identified through consultation of drug compendia. Clinical studies, case reports and summaries of product characteristics of all identified drugs were also searched. A typical example of a DDI that is often observed in children is that involving valproate (VPA) and carbapenem antibiotics. This DDI has a unique mechanism of action (inhibits the enzyme that catalyses the hydrolysis of VPA\u2010glucuronide) and leads to a fall of around 60% of VPA level, associated with seizure recurrence. An example of bidirectional DDI involves the antimycotic voriconzole and several ASMs. Voriconazole is metabolized and is a strong inhibitor of cytochrome (CYP)3A4, CYP2C9\/10 and CYP2C19. There is clinical evidence of induction of voriconazole metabolism with possible loss of its efficacy by phenytoin (PHT), while voriconazole increases the levels of PHT. Other ASMs that are inducers of these enzymes, such as carbamazepine (CBZ), phenobarbital, stiripentol and to a lesser degree, oxcarbazepine, might be predicted to decrease the level of voriconazole. Voriconazole might also be predicted to increase levels of cannabidiol, CBZ, lacosamide, midazolam, and zonisamide. DDIs between ASMs and some antiviral agents are potentially even more frequent and clinically relevant.<\/jats:p>","DOI":"10.1684\/epd.2021.1261","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T13:30:49Z","timestamp":1620912649000},"page":"229-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children"],"prefix":"10.1002","volume":"23","author":[{"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[{"name":"Regional Health Agency of Tuscany Firenze Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Department of Experimental and Clinical Medicine Marche Polytechnic University Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003509"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2014.0714"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2003.011593"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-020-00345-5"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0933"},{"issue":"4","key":"e_1_2_11_7_1","first-page":"354","article-title":"Medication use and potential drug interactions in pediatric patients with infectious diseases","volume":"22","author":"Lisby S.M.","year":"1987","journal-title":"Hosp Pharm"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.05.038"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13249"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.5_suppl_2.S17"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02237.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.13"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0067-4"},{"key":"e_1_2_11_14_1","unstructured":"ATC code.https:\/\/www.atccode.com\/. [Accessed on February 2020]."},{"key":"e_1_2_11_15_1","unstructured":"Medscape interaction checker.https:\/\/reference.medscape.com\/drug-interactionchecker. [Accessed on May 2020]."},{"key":"e_1_2_11_16_1","unstructured":"Liverpool Interaction COVID-19 drugs.https:\/\/www.covid19-druginteractions.org\/Detailedrecommendations for interactions with experimental COVID-19 antiviral therapies.https:\/\/www.covid19-druginteractions.org\/prescribing-resources. [Accessed April 2020]."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.13001.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00409-5"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0897-4"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1072"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0088-z"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.12.003"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062174"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-7647-4_5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720208784310196"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.153"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206938"},{"key":"e_1_2_11_28_1","unstructured":"Brivaracetam SPC.https:\/\/www.medicines.org.uk\/emc\/product\/1963\/smpc. [Accessed on April 2020]."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1234"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.20179"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12501"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2004.03.014"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2014.12.010"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0413-2"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1054002"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000316"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000201"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198207000-00008"},{"key":"e_1_2_11_39_1","first-page":"992","article-title":"Primidone intoxication associated with concurrent use of chloramphenicol","volume":"182","author":"Campbell C.L.","year":"1983","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.9.1227"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1991-z"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03593.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001760"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3402\/gha.v7.25370"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03335.x"},{"key":"e_1_2_11_46_1","unstructured":"Cobicistat SPC.https:\/\/www.medicines.org.uk\/emc\/product\/3466\/smpc. [Accessed May 2020]."},{"key":"e_1_2_11_47_1","unstructured":"Ritonavir SPC.https:\/\/www.medicines.org.uk\/emc\/product\/221. [Accessed May 2020]."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00006"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000715"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417751961"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx461"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4328-4331.2004"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.04.014"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.106"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1953"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1086\/504952"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.02.010"},{"key":"e_1_2_11_58_1","first-page":"707","article-title":"Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents","volume":"17","author":"Granot E.","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.079038"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-9151-4_1"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-020-00343-7"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.08.004"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4896"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2012.07.009"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-8-18"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G418"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.62"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02391.x"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719831974"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01997.x"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.087007"},{"key":"e_1_2_11_72_1","unstructured":"RxList.https:\/\/www.rxlist.com\/drug-interaction-checker.htm. [Accessed on May 2020]."},{"key":"e_1_2_11_73_1","unstructured":"Liverpool Interaction checker.https:\/\/www.hiv-druginteractions.org\/. [Accessed April 2020]."},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01561.x"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2021.1261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:08:51Z","timestamp":1710778131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2021.1261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1684\/epd.2021.1261"],"URL":"https:\/\/doi.org\/10.1684\/epd.2021.1261","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}